Treatment that can reduce deaths from covid

Fourth dose of Covid vaccine ‘holes’: 40% of those over 60 have not received it

he Anticoagulant treatment in high doses It can reduce the death rate 30 percent and the need for intubation in 25 percent of those hospitalized for COVID-19 who are not in critical condition, according to the results of the international ‘FREEDOM’ trial, led by the Director General of the National Center for Cardiovascular Research (CNIC), President of Mount Sinai Heart and Chief Physician of Mount Sinai Hospital in New York (USA), Valentine Foster.

This is the first study to show that high-dose anticoagulants can improve survival in these patients, prof An important discovery As deaths from Covid-19 are still prevalent around the world, especially in less developed countries.

“We have learned that many patients hospitalized for Covid-19 who have lung involvement, but who are not admitted to intensive care (ICU), will benefit from Subcutaneous enoxaparin treatment in high doses or in high dosesoral [medicamentos anticoagulantes] To prevent Coagulation and disease progression,” commented Dr. Foster.

At the start of the pandemic, Foster realized that many hospitalized patients with Covid-19 had developed high levels of COVID-19 Life-threatening blood clots.

Their research showed that prophylactic treatment (with a low dose) of anticoagulants was associated with better outcomes, both in and out of the intensive care unit among patients hospitalized for Covid-19. The researchers also noted that Therapeutic anticoagulation (in higher doses) it can lead to better results.

For this reason, they designed this randomized trial to identify it The most effective regimen and dose To improve outcomes for non-critical hospitalized Covid-19 patients.

Between August 26, 2020, and September 19, 2022, they were recruited 3,398 adult patients have been hospitalized for Covid-19 Confirmed (mean age, 53 years) from 76 hospitals in 10 countries, including Spain.

The patients They were not admitted to the intensive care unit or intubatedAnd nearly half of them showed signs of Covid-19 affecting their lungs, causing it Acute respiratory distress syndrome (ARDS).

Participants were randomized to receive doses of Three different types of anticoagulants over the next 24-48 hours Upon admission to the hospital they were followed for 30 days.

Equal numbers of patients were treated with each of the three drug regimens: Subcutaneous prophylactic enoxaparin, subcutaneous therapeutic enoxaparin, and oral therapeutic apixaban. The combined treatment groups were compared with the preventive group.

cprimary endpointOr it was a combination of death, needing intensive care unit care, systemic thromboembolism, or stroke in 30 days.

Although this criterion was not significantly reduced between groups, The 30-day mortality rate was lower in patients treated with therapeutic anticoagulants (high dose) than those on the preventive regimen (low dose).

Thus, 7% of patients who were treated with prophylactic anticoagulants died within 30 days, compared to 4.9% of the other group, which is an overall decrease of 30%.

Regarding the need for intubation, It also decreased in the treatment group: 6.4 percent of patients were intubated within 30 days, compared to 8.4 percent in the prophylactic group, a decrease of 25 percent.

The study showed that therapeutic anticoagulation was particularly beneficial for patients Patients with acute respiratory distress. Among patients with acute respiratory distress syndrome at hospital admission, 12.3 percent in the prophylactic anticoagulation group died within 30 days, compared with 7.9 percent in the curative anticoagulant group.

All groups submitted Low bleeding rates There are no differences between the two therapeutic materials in terms of safety and effectiveness.

“Information is critical for managing patients with Covid-19 who are sick enough to require hospitalization, but not sick enough to require ICU treatment. It prevents disease progression, especially the need for intubation, and saves lives. This is especially important, because Covid-19 is not going away. In the United States, the current number of daily deaths, while much lower than it was at the height of the pandemic, is double what it was just a year ago. And in other countries, Covid-19 is wreaking havoc,” says Greg W. Stone, co-principal investigator of the detailed study.

The results were presented during the Scientific Sessions of the American College of Cardiology held in conjunction with the World Congress of Cardiology in New Orleans (USA) and were simultaneously published in the scientific journal Journal of the American College of Cardiology.